Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
P/B ratio for Insmed Incorporated (INSM)
P/B ratio as of 2023: -13.11
According to Insmed Incorporated's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -13.11. At the end of 2022 the company had a P/B ratio of 27.95.
P/B ratio history for Insmed Incorporated from 1999 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -13.11 |
| 2022 | 27.95 |
| 2021 | 7.44 |
| 2020 | 11.78 |
| 2019 | 7.72 |
| 2018 | 4.84 |
| 2017 | 5.75 |
| 2016 | 5.30 |
| 2015 | 3.41 |
| 2014 | 3.57 |
| 2013 | 4.15 |
| 2012 | 1.47 |
| 2011 | 0.53 |
| 2010 | 0.43 |
| 2009 | 0.79 |
| 2008 | -20.23 |
| 2007 | 8.24 |
| 2006 | 6.04 |
| 2005 | 9.12 |
| 2004 | 11.90 |
| 2003 | 4.03 |
| 2002 | 0.62 |
| 2001 | 2.10 |
| 2000 | 0.66 |
| 1999 | 11.67 |